Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gilead Sciences (NQ: GILD ) 76.72 +0.82 (+1.08%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 6,847,055 Open 76.09 Bid (Size) 76.00 (1) Ask (Size) 76.98 (1) Prev. Close 75.90 Today's Range 75.91 - 77.12 52wk Range 62.07 - 87.86 Shares Outstanding 1,253,809,440 Dividend Yield 3.91% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News $100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today August 22, 2024 Via Benzinga Gilead Sciences to Present at Upcoming Investor Conferences August 21, 2024 From Gilead Sciences, Inc. Via Business Wire Performance YTD -7.83% -7.83% 1 Month +0.27% +0.27% 3 Month +19.99% +19.99% 6 Month +5.17% +5.17% 1 Year -0.18% -0.18% More News Read More Biotech Bull Market: 3 Ways To Play It August 20, 2024 Via Talk Markets Topics Economy Exposures Interest Rates Peering Into Gilead Sciences's Recent Short Interest August 20, 2024 Via Benzinga Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs August 16, 2024 Via Benzinga Topics Lawsuit Exposures Financial Legal Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts August 15, 2024 Via Benzinga Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat August 08, 2024 Via Investor's Business Daily $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today August 06, 2024 Via Benzinga FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal August 15, 2024 Via Benzinga Exposures Product Safety Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA August 14, 2024 From Gilead Sciences, Inc. Via Business Wire 7 Defensive Stocks to Buy as Investors Seek Shelter August 14, 2024 Via InvestorPlace 3 Stocks Retirees Should Absolutely Love August 10, 2024 Via The Motley Fool Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels August 09, 2024 Via Benzinga Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday? August 09, 2024 Via Benzinga Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript August 08, 2024 Via The Motley Fool Topics Earnings Exposures Financial GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q2 2024 August 08, 2024 Via InvestorPlace Gilead Sciences Announces Second Quarter 2024 Financial Results August 08, 2024 From Gilead Sciences, Inc. Via Business Wire Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday? August 08, 2024 Via Benzinga Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until... August 08, 2024 Via Benzinga Topics Economy Stocks Exposures Economy US Equities Four Stocks To Watch This Week - Monday, August 5 August 05, 2024 Via Talk Markets 2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off August 03, 2024 Via The Motley Fool Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List August 02, 2024 Via InvestorPlace Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet August 02, 2024 Via Benzinga The Top 3 Biotech Stocks to Buy Now Summer 2024 July 31, 2024 Via InvestorPlace Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? July 31, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.